藍帆醫療(002382.SZ):“年產1000萬套急救包項目”現已正式投產
格隆匯11月3日丨藍帆醫療(002382.SZ)公佈,公司下屬子公司在湖北省黃岡市團風縣投資建設的“年產1000萬套急救包項目”從2021年7月開工建設,現已正式投產,全部達產後公司護理事業部核心產品急救包產能將獲得約一倍提升。
此次投產項目為公司下屬子公司在團風縣新建的“醫療護理和疾控感染防護用品智能製造項目”的重要組成部分,現已建成目前國內最大的急救包單體生產車間。該項目還包括自動化設施設備、檢驗中心等,不僅解決了當下的急救包產能瓶頸,更進一步提高了急救包生產效率,為護理事業部重點突破美國等市場提供有力支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.